For US Healthcare Professionals Only. If you are seeking global VELTASSA information, please click here.
VELTASSA® (patiromer) for oral suspension
Important Safety Information INDICATION
VELTASSA is indicated for the treatment of hyperkalemia. Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.
WARNINGS AND PRECAUTIONS Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post‑operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies. Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.
Most Common Adverse Reactions: The most common adverse reactions (incidence ≥2%) were constipation (7.2%), hypomagnesemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.
Full Prescribing Information Patient Site Patient Support Services
 

CONSIDER VELTASSA
Start once daily, stay once daily


An unflavored, drinkable suspension for your patients

Recommended Starting Dose

8.4 g/day

Titration

At weekly intervals:
can be increased or decreased by 8.4 g/day up to a maximum of 25.2 g/day*

Dosing Strengths

8.4 g/day
16.8 g/day
25.2 g/day
  1/3 cup of water

Administer other oral medications at least 3 hours before or after VELTASSA

*Adjust the dose based on the serum potassium (K+) and the desired target range.

Ensure your patients know how to take VELTASSA

VELTASSA is an off-white to light-brown powder taken with 1/3 cup of water.

MIX

MIX half of the water with entire packet contents, then stir.

ADD

ADD the other half of the water and stir.

DRINK

DRINK immediately. Add additional water and drink as needed to ensure entire dose is administered.



Instructions for patients:

Take with or without food.

  • DO adhere to prescribed diet
  • DO mix VELTASSA with water only
  • DO mix with water in separate steps to avoid clumping
  • DO NOT take other oral drugs less than 3 hours before or after taking VELTASSA to avoid possible interaction
  • DO NOT heat VELTASSA or add to heated foods or liquids
  • DO NOT mix VELTASSA in a blender
  • DO NOT take in dry form


 

Items your patients will need to take VELTASSA:

Veltassa Packet

Scissors

Glass

1/3 cup of water

Spoon

No interactions when VELTASSA and other oral medications are taken 3 hours apart

Drug Interactions
DRUGSIN VITROIN VIVO*
ciprofloxacin levothyroxine metformin amlodipine cinacalcet clopidogrel furosemide lithium metoprolol trimethoprim verapamil warfarin acetylsalicylic acid allopurinol amoxicillin apixaban atorvastatin cephalexin digoxin glipizide lisinopril phenytoin riboflavin rivaroxaban spironolactone valsartan

*Drugs tested in in vitro binding studies. Drugs that showed an in vitro interaction were subsequently tested in vivo to determine dose separation. There was no interaction when VELTASSA and these drugs were taken 3 hours apart.

Important Safety Information, including Boxed WARNING

Indication

VELTASSA is indicated for the treatment of hyperkalemia.
Limitation of Use: VELTASSA should not be used as an emergency treatment for life‑threatening hyperkalemia because of its delayed onset of action.


Important Safety Information

CONTRAINDICATIONS
  VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

 

WARNINGS AND PRECAUTIONS
  Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post‑operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.

Most Common Adverse Reactions: The most common adverse reactions (incidence ≥2%) were constipation (7.2%), hypomagnesemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.

Please click here for full Prescribing Information.



References: 1. Cipro® (ciprofloxacin hydrochloride) Tablets [package insert]. Bayer Healthcare Pharmaceuticals, Inc. rev 07/16. 2. Levoxyl® (levothyroxine sodium) Tablet [package insert]. King Pharmaceuticals, Inc. rev 11/07.

Indication

VELTASSA is indicated for the treatment of hyperkalemia. Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

Important Safety Information

CONTRAINDICATIONS VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.
WARNINGS AND PRECAUTIONS
Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post‑operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies. Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels. Most Common Adverse Reactions: The most common adverse reactions (incidence ≥2%) were constipation (7.2%), hypomagnesemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.